“The forthcoming agreement with Sanofi will give all member states the opportunity to purchase the vaccine,” the commission said in a statement.
“We have advanced in the debates with several other companies. Now that we do not know which vaccine will work best in the end, Europe is investing in a diverse portfolio of promising substances that come from different technologies. This increases our chances of getting a virus fight quickly, “said Commission Chief Ursula von der Leyen.
There are currently more than 150 possible covid-19 vaccines at various stages of development. For example, the AstraZeneca vaccine, in which researchers from Oxford University are collaborating, is in an advanced stage of testing. The AZD1222 vaccine, according to a study by The Lancet, has no side effects.
Pfizer is developing its vaccine in collaboration with the German biotechnology company BioNTech and still has an extensive third phase of clinical trials ahead of it. According to recently published results in the first round of testing, one of its experimental vaccines elicited the desired immune system response in some patients.
This week, the Minister of Health Adam Vojtech stated that according to current calculations, the Czechia would need about 3.5 million doses of the covid-19 vaccine.